Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S‐1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer
Author:
Affiliation:
1. Department of SurgeryFaculty of Medicine, Kindai UniversityOsakasayama Japan
2. Clinical Research Center, Kindai University HospitalOsakasayama Japan
3. Division of PharmacotherapyFaculty of Pharmacy, Kindai UniversityHigashiosaka Japan
Publisher
Wiley
Subject
Oncology,General Medicine,Surgery
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.25295
Reference20 articles.
1. Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
2. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
3. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies
4. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)
5. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations;Current Oncology;2024-03-09
2. A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial;Journal of Gastrointestinal Oncology;2023-04
3. The safety and efficacy of laparoscopic gastrectomy for patients with locally advanced gastric cancer following neoadjuvant chemotherapy;Scientific Reports;2022-06-20
4. Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer;Clinical and Experimental Medicine;2022-04-16
5. Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway;Journal of International Medical Research;2022-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3